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1. Introduction 
The remarkable impact of natural products (NPs) in the quest for new agents and new 
directions in medicinal discovery is well established. The exploration of Nature as a source 
of novel active agents that may serve as leads and scaffolds for drugs targeting a myriad of 
diseases and the use of synthetic organic chemistry to modify them have been a driving 
force for drug discovery. Worldwide, prostate cancer (PC) is the second leading cause of 
death after lung cancer on both USA and Australia, and the third after lung and colo-rectal 
cancers in Europe. The heavy burden of PC is further exemplified by the fact that it accounts 
for about 1 in 4 newly diagnosed cancers each year among USA men, and in 2010, 
approximately 32,050 men are expected to die from this disease in the USA alone whereas in 
Europe 2.5 million cases of PC are freshly diagnosed every year, 9% of which prove fatal. PC 
is a slow progressing disease found to be primarily dependent on androgens which are 
involved in its development, growth and progression. Transition into a hormone-refractory 
state typically occurs in less than 2 years following the onset of the common androgen 
deprivation therapies available. Thus, a relevant issue on PC drug discovery is the ability to 
target both androgen-dependent and –independent cells in order to avoid recurrence 
phenomena which could be accomplished by multi-target agents. NPs from various sources 
have been tested on PC-related targets with promising results. Recent research has brought 
into light compounds such as iejimalide B, spisulosine, pristimerin, celastrol, withaferin A, 
and several other pentacyclic triterpenoids such as betulinic, ursolic, and boswellic acids 
which show promise for future drug development. Other examples include the synthetic 
epothilone ixabepilone A, the gossypol-derived AT-101, the triptolide derivative PG490-
88Na, irofulven, trabectedin, the rapamycin derivative temsirolimus, and docetaxel which is 
currently first-line therapy for castration-resistant PC combined with prednisone. This 
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chapter will highlight significant contributions of NPs and NP-derived agents on PC drug 
discovery starting from their action on PC-related targets and focusing on molecules which 
have proceeded into clinical trials. 
2. Natural products and cancer 
Over the course of millennia, natural compounds have evolved into specific scaffolds that 
interact with cellular macromolecules (Clardy & Walsh, 2004). Such scaffolds can be used as 
templates and fine-tuned by medicinal chemists to produce novel compounds with 
therapeutic applications. Indeed, about 40% of drugs used today are derived from natural 
plant, animal or microbial sources (Carlson, 2010). A total of 13 NPs and NP-derived drugs 
were approved for marketing worldwide from 2005 to 2007, out of which ziconotide (Prialt®, 
Elan), exanetide (Byetta®, Eli Lilly and Amylin Pharmaceuticals), retapamulin (Altabax® or 
Altargo®, GSK), trabectedin (Yondelis®, ET-743, J&J), and ixabepilone (Ixempra®, BMS-
247750, Bristol-Meyers Squibb) were members of new human drug classes (Butler, 2008). 
These compounds are depicted on Figure 1. 
Historically, the development of a NP lead has been limited by availability and structural 
complexity of the parent natural compounds (Cragg et al., 2009). NPs are often produced in 
trace quantities, and biomass is limited or, in the case of microbial sources, unculturable. To 
circumvent such difficulties as extraction, assay-based functional fractionation, isolation, 
characterization, and target validation, classical drug-discovery has been gradually replaced 
by molecular target-based drug discovery (Ojima, 2008). This approach uses high-
throughput screening of large libraries of compounds, lead identification from hits, and lead 
optimization, computational and structural biology, and has become a main stream in the 
past two decades. Nonetheless, sorafenib mesylate remains the only de novo combinatorial 
drug approved by the Food and Drug Administration (FDA) to date and is used for the 
treatment of advanced renal cancer (Newman & Cragg, 2007). 
It is therefore clear that Nature will continue to be a major source of new drug leads, 
including anticancer agents. Newman & Cragg have recently reported that in the period of 
1981 to 2006, out of 100 new chemical anticancer entities only 22.2% were totally synthetic 
(Newman & Cragg, 2007). Expressed as a proportion of the nonbiologicals/vaccines, 77.8% 
were either NPs per se or were based thereon, or mimicked NPs in one form or another. 
Recent success examples of NP-derived anticancer agents approved for marketing 
worldwide include temsirolimus (Torisel®, CCI-779, Fig.1), a semi-synthetic derivative of 
sirolimus (rapamycin, rapamune) which is an immunosuppressant first isolated from the 
bacterium Streptomyces hygroscopicus (Butler, 2008). It was approved in the US in May 2007 
and Europe in November 2007 for the treatment of advanced renal cell carcinoma. 
Temsirolimus is the first mammalian target of rapamycin (mTOR) inhibitor approved for 
use in oncology. Trabectedin (Fig.1), a tetrahydroisoquinoline alkaloid produced by the 
ascidian Ecteinascidia turbinata was approved by the European Medicines Agency (EMA) in 
September 2007 for the treatment of advanced soft tissue sarcoma. Trabectedin is in Phase III 
clinical trials for the treatment of ovarian cancer and other ongoing Phase II trials include 
paediatric sarcomas, breast and prostate cancers (Butler, 2008). Also, ixabepilone (Fig. 1), a 
semi-synthetic derivative of epothilone B (Fig. 1) was approved in October 2007 by the FDA 
for the treatment of breast cancer, either as monotherapy or in combination with 
capecitabine (Butler, 2008, Toppmeyer & Goodin, 2010). 
www.intechopen.com
 
Highlights of Natural Products in Prostate Cancer Drug Discovery 465 
 
Fig. 1. NPs approved for marketing which constitute new human drug classes (2005-2007). 
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3. Prostate cancer worldwide 
PC is a common disease worldwide. Apart from skin cancer, PC is one of the most common 
cancers in men in developed countries such as the USA and Australia, as well as in the 
European Union (Black et al., 1997, Greenlee et al., 2000, Jemal et al., 2011, Jemal et al., 2010). 
It is also a leading cause of mortality and the second most common cause of cancer-related 
death in both the USA and Australia, and the third most common cause of cancer-related 
death in the European Union (Jemal et al., 2011, Jemal et al., 2010). 
PC is a hormone-sensitive cancer that is influenced by androgens such as testosterone, 
produced from cholesterol mainly in the testis but also in the adrenal glands as well as in 
other tissues including prostate tissue (Moreira et al., 2008, Schrijvers et al., 2010). 
Dihydrotestosterone, the main metabolite of testosterone, is the principal ligand for the 
androgen receptor (AR). After transfer from the cytoplasm to the nucleus, this ligand-
receptor complex activates different pathways involved in cell cycle progression and cell 
division. Huggins & Hodges introduced androgen deprivation as therapy (ADT) for 
advanced and metastatic PC in 1941 (Huggins & Hodges, 1941, Huggins et al., 1941) and 
ever since this strategy has been applied for advanced PC treatment. Thus, in patients 
with metastatic PC which are symptomatic and have rapidly increasing levels of prostate-
specific antigen (PSA), standard first-line treatment is castration either by bilateral 
orchietomy or by biochemical methods using luteinizing hormone-releasing hormone 
(LHRH) agonists (Antonarakis & Carducci, 2010, Harzstark & Small, 2010). This 
procedure is effective in about 80 to 90% of patients. However, transition into a hormone-
refractory state will typically occur in less than 2 years following the onset of the common 
ADTs. There is evidence that AR-mediated signaling and gene expression can persist in 
metastatic castrate-resistant PC (mCRPC), even in the face of castrate levels of androgen 
(Chatterjee, 2003, Debes & Tindall, 2004, Sartor, 2011). This may be due in part to the 
upregulation of enzymes involved in androgen synthesis, the overexpression of AR, or the 
emergence of mutant ARs with promiscuous recognition of various steroidal ligands. 
Patients with castrate-resistant PC (CRPC) can be offered antiandrogens in addition to 
castration which results in response in 33% of individuals (Harzstark & Small, 2010). In 
case of progression, antiandrogen withdrawal results in response in about 5 to 20% of 
patients (Harzstark & Small, 2010). Other options include secondary hormonal therapy 
using mainly ketoconazole due to its ability to inhibit cytochrome P450 17D-hydroxylase 
C17,20-lyase (CYP17), one of the enzymes responsible for the biosynthesis of androgen 
precursors in the human body (Moreira et al., 2008). Despite its efficacy and ease of 
administration, ketoconazole bears several side effects (De Felice et al., 1981, Lake-Bakaar 
et al., 1987). Patients with CRPC are currently treated with docetaxel (Fig. 5) 
chemotherapy and prednisone which improves survival time in about 18 months 
(Mancuso et al., 2007, Harzstark & Small, 2010). Nonetheless, patients with CRPC will die 
of their cancer and thus new treatments are required (Lassi & Dawson, 2010, Sartor, 2011). 
Two additional treatment options for mCRPC patients have been recently established in 
the “post-docetaxel space.” Therapy with cabazitaxel (Fig. 5) and prednisone or treatment 
with the CYP17 inhibitor and antiandrogen abiraterone (also combined with prednisone) 
has been shown to improve survival in patients with mCRPC following docetaxel therapy 
(Sartor, 2011). Compared with mitoxantrone/prednisone, cabazitaxel/prednisone 
significantly improved overall survival, with a 30% reduction in rate of death, in patients 
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with progression of mCRPC. Similarly, abiraterone acetate plus prednisone significantly 
decreased the rate of death by 35% compared with placebo plus prednisone in mCRPC 
patients progressing after prior docetaxel therapy (Sartor, 2011). 
A relevant issue on PC drug discovery is the ability to target both androgen-sensitive and 
androgen-insensitive cells in order to avoid recurrence phenomena, which could be 
accomplished by multi-target drugs. In addition, androgen-insensitive PC cells have a very 
low rate of proliferation (Nemoto et al., 1990). Less than 10% of such cells proliferate during 
a given day thus leaving an extremely small therapeutic index for anti-proliferation drugs. 
The development of new drugs that can delay the onset and/or progression of human PC is 
therefore bound to have a significant impact on disease-related cost, morbidity and 
mortality for a large fraction of the world population. 
4. Natural products and prostate cancer 
4.1 Marine compounds 
The preclinical pipeline continues to supply several hundred novel marine compounds 
every year and those continue to feed the clinical pipeline with potentially valuable 
compounds (Singh et al., 2008, Mayer et al., 2010). Thus, in the US there are three FDA 
approved marine-derived drugs, namely cytarabine (Cytosar-U®, Depocyt®, Fig. 2), 
vidarabine (Vira-A®, Fig. 2) and ziconotide (Fig. 1). The current clinical pipeline includes 13 
marine-derived compounds that are either in Phase I, Phase II or Phase III clinical trials. 
Several key Phase III studies are ongoing and there are seven marine-derived compounds 
now in Phase II trials (Mayer et al., 2010). 
 
 
 
 
Fig. 2. FDA-approved marine-derived products 
Several marine-derived products have been tested on PC targets. Iejimalides A-D (Fig. 3), 
24-membered ring lactones bearing an N-formyl serine terminated side chain, are a class of 
marine macrolides found in the tunicate Eudistoma cf. rigida, a species of marine tunicate 
native to coral reefs in the vicinity of Ie Island (Iejima) near Okinawa in Japan, which have 
been found to be cytotoxic against a wide range of cancer cells at low nanomolar 
concentrations (Schweitzer et al., 2007, McHenry et al., 2010). The effects of iejimalide B were 
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studied on LNCaP and PC-3 cells (Wang et al., 2008). On LNCaP cells, the compound 
induced a dose-dependent G0/G1 arrest and apoptosis, after 48 hours of treatment. 
Iejimalide B was found to modulate the steady-state levels of many gene products 
associated with the cell cycle and death, however, the same concentrations of compound 
initially induced a G0/G1 arrest followed by S phase arrest on PC-3 cells, without triggering 
apoptosis (Wang et al., 2008). Increased expression of the cyclin kinase inhibitor p21WAF1/CIP1 
and downregulation of cyclin A expression were also observed with no modulation of the 
genes associated with cell death. Comparison of the effects of iejimalide B  on the two cell 
lines suggested that the compound induced cell cycle arrest by two different mechanisms 
and that the induction of apoptosis on LNCaP cells was p53-dependent (Wang et al., 2008). 
 
 
 
 
 
 
Fig. 3. Marine-derived compounds with impact on PC 
Spisulosine (PharmaMar, ES-285, Fig. 3) is a novel anti-cancer agent recently isolated from 
the sea mollusc Spisula polynyma which inhibits the growth of several solid tumor cell lines 
(Padron & Peters, 2006) including human prostate PC-3 and LNCaP cells with an IC50 of 1-10 
PM, through intracellular accumulation of ceramide and activation of the atypical protein 
kinase isoform PKCǇ (Sanchez et al., 2008). Thus, intracellular ceramide levels were 
increased after 48 hours of treatment with spisulosine. Both fumonisin B1, a mycotoxin 
produced by Fusarium verticillioides and a reported inhibitor of ceramide synthase, and 
myriocin, a potent fungal inhibitor of serine palmitoyltransferase, prevented this effect 
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pointing to a de novo synthesis of ceramide in the mechanism of action of spisulosine on PC 
cells. The same effect was not observed with specific inhibitors of the stress-related mitogen 
activated protein (MAP) kinases as well as of the peroxisome proliferator-activated receptor 
(PPARJ), phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt), and classical protein 
kinases C (PKCs) pathways, rulling out interference of these pathways in the mechanism of 
action of spisulosine (Sanchez et al., 2008). Spisulosine entered Phase I clinical trials in 
patients with solid tumors. A dose-escalation study evaluated the safety, pharmacokinetics, 
pharmacogenomics, and efficacy of ES-285 in adult cancer patients (Baird et al., 2009). ES-285 
showed an acceptable safety profile at doses up to 128 mg/m2. At this dose level, 
pharmacokinetic data indicated that pharmacologically relevant concentrations had been 
achieved, and pharmacogenomic studies indicated consistent, dose-responsive changes in 
expression of genes of potential biological relevance. This study identified transaminitis and 
neurotoxicity as the dose-limiting toxicities associated with a 24-hour infusion of ES-285 
given once every 3 weeks (Baird et al., 2009). These schedule independent hepato- and 
neuro-toxicity events caused the discontinuation of the clinical development of ES-285 (Vilar 
et al., 2010, Schoffski et al., 2011). 
As previously mentioned, trabectedin (Fig. 1) is currently under phase II/III development in 
breast cancer, hormone-resistant PC (HRPC), sarcomas, and ovarian cancer (Bayes et al., 
2004, Michaelson et al., 2005, Zelek et al., 2006, Carter & Keam, 2007). Trabectedin binds to 
the minor groove of DNA and forms covalent bonds at the N2 position of guanidine (Marco 
et al., 2006). Two of the tetrahydroisoquinoline rings recognize and bind to the minor groove 
of the DNA double helix whereas the other ring protrudes out of the minor groove and 
interacts directly with transcription factors. Trabectedin bends DNA towards the major 
groove rather than towards the site of interaction, unlike other compounds that bind to the 
minor groove (Carter & Keam, 2007). The cytotoxicity of this compound towards cancer cells 
has been explained mostly by its interference with the transcription-coupled nucleotide 
excision repair (TC-NER) pathway (Carter & Keam, 2007). Sensitization of the death 
receptor pathway has been recently reported to be essential in amplifying the cytotoxic 
properties of trabectedin and to account for the hepatotoxicity observed in patients treated 
with this drug (Martinez-Serra et al., 2011). Both in vitro and in vivo activities have been 
found for trabectedin against a range of tumor cells lines, human xenografts, and human 
tumor explants, including STS, ovarian, breast, prostate and renal cancers, melanoma, and 
non-small cell lung cancer (NSCLC) (Li et al., 2001, Carter & Keam, 2007). Unlike most 
anticancer drugs, the mechanism of resistance to trabectedin does not appear to involve P-
glycoprotein (Carter & Keam, 2007). 
Recently, a specific inhibitor of AR-dependent tumour growth that does not exhibit toxicity 
at a therapeutic dose range has been identified (Skinner, 2010, Thompson, 2010). EPI-001 
(Fig. 3) has a new mode of action, as it targets the transactivation of AR regardless of the 
presence of androgen, and is a promising therapy to delay the progression of CRPC. This 
compound was first isolated from the marine sponge Geodia lindgreni by Sadar et al. which 
immediately identified its similarity to BADGE (bisphenol A diglycidic ether) and realized 
that it must be of industrial origin (Andersen et al., 2010). The collected sponge presumably 
bioaccumulated the BADGE derivatives from contaminated seawater. EPI-001 was first 
isolated and purified and afterwards synthesized in order to be tested on PC targets. Thus, 
EPI-001 blocked transactivation of the amino-terminal domain of the AR and was specific 
for its inhibition without attenuating transcriptional activities of related steroid receptors 
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(Andersen et al., 2010). EPI-001 interacted with the AF-1 region, inhibited protein-protein 
interactions with AR, and reduced AR interaction with androgen-response elements on 
target genes. Importantly, EPI-001 blocked androgen-induced proliferation and caused 
cytoreduction of CRPC in xenografts dependent on AR for growth and survival without 
causing toxicity (Andersen et al., 2010). 
4.2 Microbial compounds 
Due to the current ability to cultivate only a vanishingly small number of naturally 
occurring microorganisms, the study of either terrestrial or marine natural microbial 
ecosystems has been severely limited (Cragg et al., 2009). Nonetheless, a most impressive 
number of highly effective microbially derived chemotherapeutic agents has been 
discovered and developed (Cragg et al., 2009, Newman & Cragg, 2009), examples of which 
are temsirolimus and ixabepilone (Fig. 1) (Butler, 2008, Toppmeyer & Goodin, 2010). The 
microbial universe thus presents a vast untapped resource for drug discovery and the 
advent of genetic techniques that permit the isolation and expression of biosynthetic 
cassettes will most likely place microbes at the frontier for NPs lead discovery. 
4.2.1 Epothilones 
Ixabepilone or aza-epothilone B (BMS-247550, Bristol-Myers-Squibb Co., Fig. 1) is a semi-
synthetic analogue of patupilone (epothilone B, EPO906, Fig. 1) which is FDA-approved 
for the treatment of breast cancer (Butler, 2008, Toppmeyer & Goodin, 2010). The 
epothilones are 16-membered macrolides isolated from the myxobacterium Sorangium 
cellulosum (Hofle et al., 1996, Gerth et al., 1996) which bind to tubulin heterodimers and 
prevent the depolymerization of microtubules with subsequent mitotic arrest and 
apoptotic cell death, in a fashion analogous to plant-derived taxanes such as paclitaxel 
(Fig. 5) (Wartmann & Altmann, 2002, Cheng et al., 2008). The main difference resides in 
the fact that taxanes are substrates for P-glycoprotein and epothilones are not, and this 
ability together with ease of formulation have been considered advantages for 
overcoming taxane resistance of tumor cells (Wartmann & Altmann, 2002, Cheng et al., 
2008). Moreover, whereas the synthesis of paclitaxel relies on 10-deacetylbaccatin III 
which is available from the needles of various Taxus species (Cragg et al., 2009), total 
synthesis of patupilone B has been accomplished (Su et al., 1997). The progress of 
epothilones in the PC setting has been extensively reviewed (Lee & Kelly, 2009, Lassi & 
Dawson, 2010, Cheng et al., 2008, Bystricky & Chau, 2011). 
Patupilone inhibits the proliferation of DU145 and TSU-Pr1 PC cells in the low nanomolar 
range causing mitotic arrest (Sepp-Lorenzino et al., 1999). Inhibition of proliferation appears 
to be dependent on the p53 status of the tumor cells (Ioffe et al., 2004). Patupilone is active in 
vivo against human PC xenografts (O'Reilly et al., 2005). It produced transient to long-lasting 
tumor regressions, including apparent cures, in s.c. transplanted DU145 and PC-3M PC 
xenografts in mice, with the 2.5 mg/kg regimen twice every 7 days being superior to a 
single dose of 4 mg/kg patupilone (O'Reilly et al., 2005). The anti-tumor activity was 
superior to that of paclitaxel, which failed to produce tumor regressions, although 
displaying a better tolerability profile. Despite the enthusiastic in vivo results, an objective 
tumor response rate of only 20% has been reported for patupilone on HRPC in which 78% of 
patients had received one (unspecified) prior line of chemotherapy, a number comparable to 
www.intechopen.com
 
Highlights of Natural Products in Prostate Cancer Drug Discovery 471 
the 12% objective tumor response obtained with docetaxel (Fig. 5) and prednisone combined 
treatment, in the phase III TAX 327 study (Larkin, 2007). In phase I trials, patupilone has 
been considered generally safe and well tolerated, with patients experiencing no severe 
neuropathy or hematologic toxicity (Rubin et al., 2005). Therefore, the safety and efficacy of 
weekly patupilone 2.5 mg/m2 were investigated in patients with CRPC in a multicenter 
phase II trial (Hussain et al., 2009). Modest response rates were observed with 2.5 mg/m2 of 
patupilone weekly for 3 weeks of a 4-week cycle and therefore development of patupilone 
in advanced PC at the dose and schedule tested was not warranted. A once every 3 weeks 
schedule with proactive antidiarrhea management appeared to be the most promising 
schedule (Hussain et al., 2009).  
Ixabepilone has demonstrated activity in patients with chemotherapy-naive metastatic 
HRPC (Hussain et al., 2005). Phase I clinical trials of ixabepilone administered i.v. as a 1 
hour infusion daily, for 5 consecutive days every 21 days, at doses of 1.5 mg/m2/day, 
displayed antitumor responses in patients with prior taxane treatment against solid 
tumors (Mancuso et al., 2007). Major adverse effects were neutropenia and neuropathy. 
Ixabepilone was also evaluated as a single agent in two first line studies. PSA response 
was observed in 30-35% of cases with an objective clinical response rate of over 15% in 
patients with measurable disease (Mancuso et al., 2007). When combined with 
estramustine phosphate (ixabepilone 35 mg/m2 i.v. on day 2 with a 280 mg oral dose of 
estramustine, 3 times/day, on days 1-5, every 3 weeks), it was found to be well tolerated 
and have antitumor activity in patients with castrate-metastatic PC (Rosenberg et al., 2006, 
Rivera et al., 2008). Second-line taxane chemotherapy after ixabepilone resulted in a 
substantial frequency of PSA declines. Although patients with ixabepilone-refractory 
disease were less likely to respond to second-line taxane chemotherapy, 36% did achieve a 
PSA response. For patients with taxane-resistant HRPC, a randomized phase II study 
compared ixabepilone to mitoxantrone/ prednisone (Mancuso et al., 2007). A PSA decline 
of over 50% was seen in 20% of patients and median survival of 13 months was found for 
patients on the mitoxantrone arm, as compared to a PSA decline of over 50% in 17% and 
median survival of 12 months for ixabepilone treatment (Mancuso et al., 2007, Rivera et al., 
2008). A recent phase II clinical trial concluded that the combination of ixabepilone and 
mitoxantrone with prednisone appears to have greater activity than either mitoxantrone 
or ixabepilone alone in the second-line setting for CRPC, and suggests at least additive if 
not synergistic activity (Harzstark et al., 2011). The combination is well tolerated, although 
some hematologic toxicity is present and dosing with pegfilgrastim is required. The 
results of this study suggest that it is appropriate to study further the ixabepilone and 
mitoxantrone with prednisone regimen in patients with docetaxel resistant CRPC 
(Harzstark et al., 2011). 
The fully synthetic epothilone sagopilone (Fig.4) (ZK-EPO, Bayer Schering Pharma AG) is 
undergoing initial testing in PC with promising results (Galmarini, 2009). In preclinical 
studies, sagopilone inhibited cell growth in a wide range of human cancer cell lines. 
Moreover, sagopilone was not recognized by multidrug-resistant (MDR)  cellular efflux 
mechanisms, and maintained its activity in MDR tumor models. Phase I clinical trials 
established that the sagopilone side-effect profile was similar to that reported for taxanes, 
with neuropathy and neutropenia being the most commonly reported toxicities (Arnold et 
al., 2009, Schmid et al., 2010). A recommended dose for phase II studies was established at 
16.53 mg/m2, once every 3 weeks (Schmid et al., 2010). Proof-of-concept has already been 
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established in patients with platinum-resistant ovarian cancer and androgen-independent 
PC, and clinical responses have been shown in patients with melanoma and small-cell lung 
cancer. Results are awaited from other ongoing trials (Schmid et al., 2010). 
 
 
Fig. 4. Microbial-derived compounds with impact on PC. 
4.2.2 mTOR inhibitors 
The protein kinase mTOR regulates protein translation, cell growth, and apoptosis (Garcia & 
Danielpour, 2008, Seeliger et al., 2007). Alterations in the pathway regulating this kinase 
occur in many solid malignancies including prostate, bladder, and kidney cancer. In vitro 
and in vivo models of prostate and bladder cancer have established the importance of the 
mTOR pathway in control of cancer progression and metastasis (Garcia & Danielpour, 2008, 
Opdenaker & Farach-Carson, 2009). The mTOR inhibitors temsirolimus (Fig. 1) and 
everolimus (RAD001, Zortress®, Novartis, Fig.4), two ester analogues of sirolimus 
(rapamycin, Fig. 1), as well as rapamycin itself have clear antitumor activity in in vitro and 
in vivo models and are under clinical trial investigations for prostate and bladder cancers 
(Seeliger et al., 2007, Armstrong et al., 2010). Ridaforulimus (deforolimus, AP23573, MK-
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8669, Merck and ARID Pharmaceuticals, Fig. 4), yet another mTOR inhibitor and a 
derivative of rapamycin is also undergoing clinical trials for PC (Gross et al., 2006, 
Squillace et al., 2008).  
Genetic alterations, including loss of phosphatase and tensin homolg (PTEN), mutation of 
the PI3K, and amplification of AKT1 and AKT2 leading to activation of Akt kinase activity 
have been linked with the development of castrate progressive PC (Seeliger et al., 2007, 
Majumder et al., 2004). It is also known that alterations of the Akt signaling cascade (mTOR 
dependent) can lead to the development of prostate intraepithelial neoplasia (Majumder et 
al., 2004). Repopulation of PTEN-negative cancer cells between courses of chemotherapy has 
been reported to be inhibited by temsirolimus on PC-3 and DU145 PC xenografts with only 
mild myelosuppression, thus suggesting its role on minimization of drug resistance in 
patients (Wu et al., 2005). In addition, the effects of concurrent and sequential administration 
of docetaxel and temsirolimus on PC-3 and LnCaP tumor cells and xenografts were studied 
(Fung et al., 2009). Temsirolimus originated greater growth delay of PC-3 xenografts than 
docetaxel alone. This effect was greater than that expected from the in vitro sensitivity, and 
differed from the general experience in treatment of human PC, where chemotherapy has 
shown greater activity than molecular-targeted agents. In contrast, for LnCaP cells, 
temsirolimus had similar inhibitory effects to those observed with PC-3 cells in culture, but 
no significant effect on LnCaP xenografts (Fung et al., 2009). Despite similar cell cycle effects 
between concurrent and sequential treatments in in vitro experiments, in vivo growth delay 
studies showed better delay of tumor regrowth with concurrent temsirolimus and docetaxel 
treatment compared to sequential treatment in the prostate xenografts (Fung et al., 2009). As 
previously mentioned, temsirolimus is the first mTOR inhibitor approved for use in 
oncology (Butler, 2008). Further results from ongoing clinical trials should help to establish 
whether a role exits for this drug on the PC setting. 
Deforolimus alone was shown to inhibit proliferation of several prostate cell lines by 
20ï60% (maximal inhibition) and as expected, sensitivity was associated with loss of PTEN 
(Squillace et al., 2008). The anti-proliferative activity of deforolimus and bicalutamide, alone 
and in combination, was determined in three cell lines representing different stages of PC 
progression. The combination was strongly synergistic in both androgen-dependent LNCaP 
and androgen-independent C4ï2 cells but only additive in RWPE-1 (normal prostate 
epithelium) cells. The data provided support for the clinical testing of deforolimus in 
combination with bicalutamide to treat androgen-dependent and -independent PC  
(Squillace et al., 2008). Also, a phase II clinical trial of deforolimus in patients with taxane-
resistant HRPC concluded that the compound is well tolerated and promotes disease 
stabilization (Gross et al., 2006). 
The ability of everolimus to enhance the cytotoxic effects of radiation on PC-3 and DU145 
cells has been reported (Cao et al., 2006). Both cell lines became more vulnerable to 
irradiation after treatment with everolimus, with the PTEN-deficient PC-3 cell line showing 
the greater sensitivity. This increased susceptibility to radiation was found to be associated 
with induction of autophagy (Cao et al., 2006). Treatment with everolimus resulted in 
growth inhibition of C4-2 cells in bone, an effect augmented by addition of docetaxel and 
zoledronic acid (Morgan et al., 2008). Moreover it had a significant impact on maintenance of 
body weight. A single phase II study evaluated the effect of everolimus in patients with 
newly diagnosed, localized PC (Lerut et al., 2005). The most frequently observed adverse 
events are common toxicity criteria grade 1 to 2 stomatitis and rash. Recently, three 
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temsirolimus analogues, homotemsirolimuses A-C (Fig. 4), were isolated from a 
temsirolimus preparation made from rapamycin and found to inhibit mTOR as well as the 
proliferation of LNCaP cells with potency comparable to that of rapamycin and 
temsirolimus (Kong et al., 2011). 
4.3 Plant compounds 
Plant-derived NPs have been an important source of several clinically useful anti-cancer 
agents (Grothaus et al., 2010, Cragg et al., 2009, Butler, 2008, Ojima, 2008). Plants continue to 
play a major role in drug discovery as evidenced by the number of promising new agents in 
clinical development based on selective activity against cancer-related molecular targets. 
One of the most noteworthy contributions of plants to this field has been the isolation of 
tubulin interactive agents such as the Vinca alkaloids and the taxanes which are the basis of 
the majority of the currently available anticancer therapies. 
4.3.1 Taxanes 
Paclitaxel (Taxol®, Bristol-Myers Squibb, Fig. 5) was first isolated from the bark of the 
Western yew tree in 1971 and found to possess unique pharmacological actions as an 
inhibitor of mitosis, differing from the Vinca alkaloids and colchicine derivatives in that it 
promotes rather than inhibits microtubule formation (Hardman & Limbird, 2001). It binds 
specifically to the ǃ-tubulin subunit of microtubules and antagonizes the disassembly of this 
key cytoskeletal protein causing mitotic arrest. Resistance to paclitaxel is associated to high 
levels of P-glycoprotein expressed by tumor cells (Hardman & Limbird, 2001). Paclitaxel is 
currently used to treat multiple cancers such as lung, ovarian, head and neck, breast, and 
advanced stages of Kaposi’s sarcoma. Modification of the side chain of paclitaxel resulted in 
the more potent analogue docetaxel (Taxotere®, Sanofi-Aventis, Fig. 5) which has clinical 
activity against breast, ovarian and NSCLC (Hardman & Limbird, 2001). The present status 
and perspectives of taxane-based regimens for cancer treatment have been thoroughly 
reviewed (Mancuso et al., 2007, Sartor, 2011). 
In 2004, the results of the two major phase III clinical trials TAX 327 and SWOG 9916 
established docetaxel as a primary chemotherapeutic option for patients with mCRPC 
(Berthold et al., 2008, Tannock et al., 2004). Outcomes of TAX 327 demonstrated that 
chemotherapy with docetaxel was a viable option that prolonged survival for patients with 
mCRPC and in addition with an extended follow-up, the survival benefit of docetaxel in the 
TAX 327 trial has persisted. In SWOG 9916, a regimen of docetaxel and estramustine was 
compared with mitoxantrone and prednisone (Petrylak et al., 2004). In this study, the 
docetaxel regimen also conferred a significant survival benefit and increased median 
survival. At present, docetaxel/prednisone remains the first-line chemotherapy of choice for 
patients with CRPC (Sartor, 2011). Combinations of docetaxel and different drug classes, 
including tyrosine kinase inhibitors, antiangiogenesis agents, and immunologic agents, have 
been the object of several studies for CRPC. Nonetheless, phase III data for combination 
therapy with docetaxel has not produced any viable therapeutic options (Sartor, 2011). 
Cabazitaxel (XRP-6258, Jevtana®, Sanofi-Aventis, Fig. 5) is a novel taxane-class cytotoxic 
agent in which two hydroxyl groups have been replaced by methoxy groups, that has 
shown efficacy in model system tumors that are resistant to paclitaxel and docetaxel (Kumar 
et al., 2010, Sartor, 2011). Multiple cases of complete regression were observed with 
cabazitaxel in studies using human tumor xenografts. Notably, long-term tumor-free 
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survival (exceeding 133 days) and complete tumor regression were seen in pancreatic 
xenografts (MIA PaCa-2), head and neck xenografts (SR475), and prostate DU145 xenografts 
(Kumar et al., 2010). In a recently published, randomized, multicenter, phase III trial 
(TROPIC), the efficacy and safety of cabazitaxel and prednisone were compared with those 
of mitoxantrone and prednisone for the treatment of mCRPC that had progressed following 
docetaxel-based chemotherapy (De Bono et al., 2010). Tumor response and PSA response 
significantly favored cabazitaxel, as did median time to tumor progression and median time 
to PSA progression. Pain response and time to pain progression were similar between the 
treatment groups (De Bono et al., 2010). Neutropenia, leukopenia, and anemia were the 
predominant toxicities associated with cabazitaxel in the study. The findings of TROPIC 
study established cabazitaxel as the first agent to prolong survival after docetaxel treatment, 
with a 30% reduction in death over mitoxantrone (De Bono et al., 2010). On the basis of these 
data, cabazitaxel has been approved by the FDA for use in patients with mCRPC who have 
progressed after docetaxel (Galsky et al., 2010, Sartor, 2011). 
 
 
Fig. 5. Taxanes. 
4.3.2 Irofulven 
Irofulven (MGI 114, NSC 683863, Pharma, Inc., Fig. 6), an anticancer agent derived from the 
mushroom natural product illudin S has been found to inhibit DU145, PC-3, and LNCaP cell 
proliferation with IC50 values of 100, 200, and 700 nM, respectively (Poindessous et al., 2003). 
The cytotoxicity of irofulven is not affected by loss of p53 or mismatch repair function, and 
the drug is not a substrate for multidrug transporters such as P-glycoprotein and MDR-1. 
Irofulven acts by alkylating cellular macromolecular targets (Liang et al., 2004). The drug is a 
potent inducer of apoptosis in various types of tumor cells, whereas it is nonapoptotic in 
normal cells. Irofulven-induced signaling was studied on LnCaP-Pro5 cells and was found 
to be integrated at the level of mitochondrial dysfunction. The induction of both caspase-
dependent and caspase-independent death pathways was consistent with pleiotropic effects, 
which include targeting of cellular DNA and proteins (Liang et al., 2004). The effect of 
irofulven on apoptosis was also reported to be largely Bcl-2 independent, a highly desirable 
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property seeing that elevated levels of this protein correlate with an increased metastatic 
potencial of cancer cells (Herzig et al., 2003). Irofulven has demonstrated activity against PC-
3 and DU145 cells as monotherapy and enhanced efficacy was displayed in combination 
with mitoxantrone or docetaxel (Van Laar et al., 2004) and these results highlighted its 
potential to be used in combination regimens in clinical trials. Thus a phase I and 
pharmacokinetic study of irofulven (0.4 mg/kg) and cisplatin (30 mg/m2) in patients with 
solid tumors concluded that the regimen was adequately tolerated with substantial evidence 
of antitumor activity observed (Hilgers et al., 2006).  Combination regiments of the same 
dosage of irofulven with capecitabine (2,000mg/m2/day) were also found safe on phase I 
clinical trials in patients with solid tumors (Alexandre et al., 2007). Other combination 
regimens with oxaliplatin were reported to be effective on docetaxel-resistant HRPC patients 
(Tchen et al., 2005). Irofulven was also reported to be active as a single agent against HPRC on 
a phase II trial (Senzer et al., 2005). Based on evidence of irofulven activity in HRPC observed 
in these prior Phase I/II studies, a randomized Phase II study in docetaxel-refractory HRPC 
patients was initiated using irofulven/prednisone or irofulven/capecitabine/predisone versus 
mitoxantrone/prednisone (Hart et al., 2006). Preliminary results suggested a longer survival 
and time to progression, a higher PSA response, and an acceptable safety profile for 
irofulven/prednisone and irofulven/capecitabine/predisone compared to mitoxantrone/ 
prednisone. Based on these data, irofulven may have a role in treating docetaxel-resistant 
HRPC patients (Hart et al., 2006).  
 
 
Fig. 6. Plant-derived compounds with impact on PC 
4.3.3 Gossypol 
Gossypol (Fig.  6), a polyphenolic compound present in cottonseed (Huang et al., 2006), was 
originally identified as a male antifertility agent. Gossypol treatment resulted in a marked 
reduction of the prostate weight of guinea-pigs and adult rats as well as induction of 
structural and functional changes of the gland somewhat similar to the ones observed after 
www.intechopen.com
 
Highlights of Natural Products in Prostate Cancer Drug Discovery 477 
castration (Moh et al., 1992, Wong & Tam, 1989). Antiproliferative and antimetastatic 
activities in androgen-independent Dunning R3327-MAT-LyLu PC cell-bearing Copenhagen 
rats have been reported with gossypol (Chang et al., 1993). The compound has also been 
reported to potently inhibit both isoforms of 5D-reductase (Chang et al., 1993). Gossypol 
inhibited the proliferation without affecting the viability of PC-3 cells with an IC50 value of 
lower than 1 ǍM, and induced a dose- and time-dependent accumulation of cells at the 
G0/G1 phase of the cell cycle (Shidaifat et al., 1996). On DU145 cells gossypol significantly 
enhanced apoptosis through downregulation of Bcl-2 and Bcl-xL and upregulation of Bax at 
the mRNA and protein levels (Huang et al., 2006). Activation of caspases 3, 8, and 9 was also 
found to occur as well as increased PARP cleavage. Thus, gossypol is a natural BH3 mimetic 
and small molecule inhibitor of Bcl-2/Bcl-xL/Mcl-1 that potently induces apoptosis in various 
cancer cell lines (Meng et al., 2008). It also significantly enhances the antitumor activity of 
docetaxel in human PC both in vitro and in vivo. Gossypol effectively reduced the viability of 
LAPC4, PC-3, and DU145 PC cells and inhibited tumor growth in a NOD/SCID xenograft 
model (Volate et al., 2010). The growth of prostate tumor initiating cells (pTICs) isolated from 
DU145 (CD44+/hi) were also inhibited. The inhibitory effects of gossypol have been attributed 
to the induction of DNA damage, which consequently leads to the stabilization of p53 and the 
activation of the mitochondrial pathway of apoptosis (Volate et al., 2010). In addition, gossypol 
was recently reported to induce autophagy in human androgen-independent PC with a high 
level of Bcl-2 both in vitro and in vivo (Lian et al., 2011). 
A derivative of gossypol, R-(–)-gossypol acetic acid (AT-101, Ascenta Therapeutics, Inc.) has 
been evaluated on a phase I/II trial as a single-agent in men with chemotherapy-naive 
castrate-resistant PC (Liu et al., 2009). The compound was well tolerated when administered 
at 20 mg/day for 21 of 28 days. Evidence of single-agent clinical activity was observed with 
PSA declines in some patients. Further investigation of AT-101 in PC thus is warranted and 
trials combining AT-101 with androgen deprivation, as well as with docetaxel 
chemotherapy are ongoing (Liu et al., 2009). 
4.3.4 Triptolide 
Triptolide (PG 490, Fig. 6) is a diterpene triepoxide purified from Tripterygium wilfordii Hook 
F (Kupchan et al., 1972) that was found to attenuate activation of p53 in response to J-
irradiation or other stresses such as hypoxia or DNA damaging drugs, in primary cultures 
of normal and malignant PC epithelial cells, despite the presence of the wild-type p53 gene 
(Girinsky et al., 1995). Moreover, triptolide inhibited LNCaP growth with an IC50 value of 10 
ng/ml (Shamona et al., 1997). Half-maximal growth inhibition of five PC cell strains, E-PZ-
10 and four cell lines derived from prostatic adenocarcinomas of Gleason grade 3/3 (E-CA-
11), 30% intraductal carcinoma / 70% Gleason grade 4 (E-CA-12) and 3/4 (E-CA-13 and E-
CA-14), was observed with 0.1 ng/ml triptolide (Kiviharju et al., 2002). Whereas low 
concentrations of triptolide induced senescence of cells with G1 arrest, higher concentrations 
(50-100 ng/ml) triggered apoptosis. However, in contrast with the previous findings, 
protein levels of p53 were significantly increased and predominantly accumulated in the 
nuclei of prostatic epithelial cells (Kiviharju et al., 2002). Nonetheless, downregulation of p53 
target gene products such as Hdm-2 and p21WAF1/CIP1 and Bcl-2 was also found to occur. 
It was suggested that triptolide may use multiple signaling pathways, some of which 
involve p53 in cells with wild-type p53, growth arrest and induction of apoptosis (Kiviharju 
et al., 2002). Clinical and experimental studies have demonstrated that triptolide has anti-
www.intechopen.com
 
Prostate Cancer – From Bench to Bedside 478 
inflammatory and immunosuppressive activities, and effectively prolongs allograft 
survival in organ transplantation including bone marrow, cardiac, renal and skin 
transplantation (Liu, 2011). 
PG490-88Na (Pharmagenesis Inc.), a water-soluble prodrug of triptolide (14-succinyl 
sodium salt) that is converted into triptolide in the serum, has been elucidated as a new 
immunosuppressant (Fidler et al., 2003). It effectively prevents acute and chronic rejection 
in organ transplantation and shows potent antitumor activity. The compound has been 
approved for phase I clinical trials for PC (Fidler et al., 2003, Kiviharju et al., 2002). 
However, the safety and side effects of triptolide for PC therapy need to be further 
elucidated. Further development of triptolide derivatives may produce promising 
anticancer drug candidate (Liu, 2011). 
4.3.5 Withaferin A 
Withaferin A (Fig. 6), a steroidal lactone purified from the medicinal plant “Indian Winter 
Cherry” or Withania somnifera, has been widely studied for its antitumor effects (Glotter et 
al., 1966). Withaferin A was inhibits the chymotrypsin-like activity of purified rabbit 20S 
proteasome (IC50 of 4.5 ǍM) and of 26S proteasome in cultured PC-3 cells, with an IC50 value 
of 10-20 ǍM, and tumors (Yang et al., 2007). Inhibition of PC tumor cellular proteasome both 
in vitro and in vivo by withaferin A was accompanied by accumulation of Bax, INB-D and 
p27, and induction of apoptosis (Yang et al., 2007). Proteasome inhibition occurred before 
the apoptotic events of caspase-3 activation with PARP cleavage and the expected 
morphological changes (rounding and condensation), on PC-3 cells, at 10 ǍM of withaferin 
A. On LNCaP cells, AR protein levels were decreased by withaferin A and apoptosis 
triggered by the same mechanisms seen on PC-3 cells (Yang et al., 2007). Treatment of 
human PC-3 xenografts with withaferin A at 4.0 and 8.0 mg/kg/day for 24 days caused 54 
to 70% inhibition of tumor growth, as compared to control, that was associated with a 28 to 
56% inhibition of proteasomal chymotrypsin-like activity. Induction of apoptosis by 
withaferin A on PC cells bears additional interest because it has been shown to be mediated 
by the cancer specific target protein (Par-4) (El-Guendy et al., 2003). Moreover, treatment of 
androgen-responsive PC cells with antiandrogens such as flutamide or bicalutamide which 
do not induce apoptosis on their own, rendered these cells amenable to apoptosis triggered 
by withaferin A. Apoptosis by withaferin A required upregulation of Par-4 expression for 
inhibition of NF-NB activity and activation of the caspase cascade (Srinivasan et al., 2007). 
Therefore, withaferin A shows promise for HRPC treatment seeing that it not only seems to 
suppress the growth of metastatic cells but can also be exploited in combination regimens 
with antiandrogens to target resistant clones. 
4.3.6 Pentacyclic triterpenoids 
Terpenoids, among which are pentacyclic triterpenoids such as betulinic, ursolic, oleanolic, 
and boswellic acids as well as pristimerin and celastrol (Fig. 7), are extensively  found in 
fruits, vegetables and medicinal plants (Salvador, 2010). This category of compounds 
exhibits multiple properties including antioxidation, anti-inflammation, anti-HIV, and 
anticancer activities (Shah et al., 2009, Petronelli et al., 2009). 
In vitro and in vivo studies indicate that pentacyclic triterpenoids caused inhibition on cell 
proliferation and tumor growth in a variety of human cancers (Salvador, 2010). Structurally 
some of the terpenoids are similar to human hormones and thus bear interest in the 
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development of drugs that target hormone-dependent cancers such as breast and prostate 
cancers (Yang & Dou, 2010). The mechanisms by which these compounds exhibit their 
anticancer activity include inhibition of the proteasome, NF-NB, and the antiapoptotic 
protein Bcl-2 (Yang & Dou, 2010, Wang & Fang, 2009). 
 
 
Fig. 7. Pentacyclic triterpenoids 
Betulinic acid (BA, Fig. 7) is a NP identified in various bark extracts and is readily 
synthesized from betulin, a major constituent of the bark of birch trees (Aggarwal & 
Shishodia, 2006). It is currently undergoing development as a therapeutic agent against 
melanoma (Tan et al., 2003). BA inhibited the proliferation of several PC cells and 
triggered apoptosis probably due to AR downregulation that led to decreased expression 
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of vascular endothelial growth factor (VEGF) and survivin, and caspase-dependent PARP 
cleavage (Chintharlapalli et al., 2007, Kessler et al., 2007). BA was shown to induce 
proteasome-dependent degradation of Sp proteins in LNCaP cells (Chintharlapalli et al., 
2007, Yao et al., 2004, Wang et al., 2003). In vivo, BA (10 and 20 mg/kg/day) inhibited 
tumor growth in athymic nude mice bearing LNCaP cell xenografts, which was 
accompanied by decreased expression of Sp1, Sp3 and Sp4 proteins and VEGF, and 
increased apoptosis in tumors from BA-treated mice (Chintharlapalli et al., 2007). In 
androgen-refractory PC-3 cells, BA effectively inhibited NF-NB binding to DNA and its 
translocation to the nucleus, INBD phosphorylation, and INB kinase complex (IKK) 
activation, and in addition sensitized cells to TNFD-induced apoptosis through 
suppression of NF-NB (Rabi et al., 2008). A major advantage in using BA for cancer 
therapy is its low toxicity. Doses as high as 500 mg/kg, administered every 4th day for 6 
weeks to athymic mice carrying human melanomas have been shown to have no 
detectable toxic side effects (Pisha et al., 1995). However, a study demonstrated that BA 
cannot be used to potentiate cell death in combination with most anticancer drugs that 
induce apoptosis via formation of topoisomerase I-DNA cleavable complexes such as 
camptothecin, staurosporine and etoposide (Ganguly et al., 2007). Thus, the compound 
inhibits all types of topoisomerase-I DNA cleavable complexes formation irrespective of 
the process of initiation, therefore disrupting the series of events that leads to cell death. 
Ursolic acid (UA, Fig. 7) is present in many plants such as Salvia officinalis and Basil (Ocimum 
sanctum) and also a constituent of several herbal medicines marketed in Asia and worlwide 
for inflammatory conditions (Aggarwal & Shishodia, 2006, Kondo et al., 2011, Kwon et al., 
2010). UA inhibits the proliferation of PC-3 and LNCaP cells with IC50 values of 32.6 and 
15.7 ǍM, respectively (Kassi et al., 2007). At 55 ǍM, induction of apoptosis is seen on PC-3 
cells with a decrease on bcl-2 gene levels. UA-induced apoptosis on human prostate 
epithelial cells has been suggested to involve caspase activation through downregulation of 
cellular inhibitor of apoptosis proteins (c-IAPs) family proteins and without mitochondrial 
dysfunction (Choi et al., 2000). On DU145 cells UA-induced apoptosis was reported to occur 
via JNK-mediated Bcl-2 phosphorylation and degradation (Zhang et al., 2009). Also, UA was 
found to overcome Bcl-2-mediated resistance to apoptosis in LNCaP androgen-independent 
cells (Zhang, Kong, Wang et al., 2010). UA inhibits cell invasion by downregulating matrix 
metalloproteinase-9 via inhibition of Akt in PC-3 cells (Zhang, Kong, Zeng et al., 2010). 
Boswellic acids, particularly acetyl-boswellic acids such as acetyl-ǃ-boswellic acid (ABA) 
and acetyl-11-keto-ǃ-boswellic acid (ABKA, Fig. 7), can be isolated to chemical homogeneity 
from the gum resins of various Boswellia species and are well-known for their anti-
inflammatory and antitumor activities (Aggarwal & Shishodia, 2006, Moussaieff & 
Mechoulam, 2009, Shah et al., 2009). It has been reported that acetyl-boswellic acids promote 
apoptosis of PC-3 cells both in vitro and in vivo by intercepting IKK activity (Syrovets et al., 
2005). In particular, AKBA has the ability to induce cell growth arrest and reduce the AR 
expression and transcriptional activity in LNCaP cells via inhibition of the Sp1 binding 
activity (Yuan et al., 2008). Both PC-3 and LNCaP cells were sensitive to AKBA-induced 
apoptosis that correlated with the activation of caspase-8 and the upregulation of death-
receptor 5 (DR5) protein most likely by induced expression of CCAAT/enhancer binding 
protein homologous protein (CHOP) protein (Lu et al., 2008). In addition, AKBA potently 
inhibits human prostate tumor growth through inhibition of angiogenesis induced by 
VEGFR2 signaling pathways (Pang et al., 2009). 
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Pristimerin (Fig. 7) is a natural compound found in the Celastraceae and Hippocrateaceae 
families that are rich in quinone-methide triterpenes (Filho et al., 2002). Pristimerin targets the 
proteasome to induce apoptosis in human PC-3 and AR-positive C4-2B cells (Yang, Landis-
Piwowar et al., 2008). Proliferation of PC-3 cells was inhibited by pristimerin (Chang et al., 
2003) with induction of apoptosis that correlated with inhibition proteasome activity (Yang, 
Landis-Piwowar et al., 2008). The IC50 value for the inhibition of purified rabbit 20S proteasome 
with pristimerin was 2.2 ǍM. Similarly, pristimerin also potently inhibited 26S proteasome 
chymotrypsin-like activity in a extract prepared from exponentially grown PC-3 cells, with an 
IC50 of 3.0 ǍM (Yang, Landis-Piwowar et al., 2008). About 40% inhibition of cellular proteasome 
activity occurred in C4-2B cells with 5 ǍM of pristimerin and was accompanied by AR 
suppression with consequent apoptosis induction. Computational modeling showed that 
pristimerin interacts with the catalytically active amino acid N-Thr of the proteasome ǃ5 
subunit (Yang, Landis-Piwowar et al., 2008). Celastrol (Fig. 7), an active compound extracted 
from the root bark of the Chinese medicine ‘‘Thunder of God Vine’’ (Tripterygium wilfordii Hook 
F.), has been used for years as a natural remedy for inflammatory conditions (Kannaiyan et al., 
2011). The anti-inflammatory effects of this triterpene have been demonstrated in animal 
models of different inflammatory diseases, including arthritis, Alzheimer’s disease, asthma, 
and systemic lupus erythematosus. Celastrol has also been found to inhibit the proliferation of 
a variety of tumor cells and suppress tumor initiation, promotion and metastasis in various 
cancer models in vivo (Salminen et al., 2010, Kannaiyan et al., 2011). Celastrol potently and 
preferentially inhibits the chymotrypsin-like activity of human PC cellular 26S proteasome at 
1-5 ǍM (Yang et al., 2006). Inhibition of the proteasome activity by celastrol is accompanied by 
suppression of AR protein expression and induction of apoptosis. The involvement of calpain  
in AR breakdown during celastrol-induced apoptosis in PC cells has been demonstrated 
(Yang, Murthy et al., 2008). By inhibiting proteasomal activity, celastrol suppresses 
proliferation, invasion and angiogenesis by inducing the apoptotic machinery and attenuating 
constitutive NF-kB activity, both in vitro and in vivo, in androgen-independent PC cell lines 
(Dai et al., 2010). Angiogenesis-mediated tumor growth is also suppressed by celastrol by 
targeting the AKT/mTOR/P70S6K pathway, (Pang et al., 2010). Celastrol sensitizes PC-3 cells 
to radiation both in vitro and in vivo by impairing DNA damage processing and augmenting 
apoptosis (Dai et al., 2009). It also potentiated the apoptotic effects of TRAIL through down-
regulation of cell survival proteins and up-regulation of death receptors via the ROS-mediated 
up-regulation of CHOP pathway on several tumor cell lines including PC (Sung et al., 2010). 
Recent research has brought into light the effects of retigeric acid B (RAB, Fig. 7), a NP 
isolated from the lichen Lobaria kurokawae Yoshim and previously exploited for its antifungal 
activity, on PC cells (Liu et al., 2010). Thus, RB was able to suppress AR expression and 
transcriptional activity in LNCaP cells, and inhibition of PC-3 cell growth was accompanied 
by induction of the S-phase cell cycle arrest as well as apoptosis. 
5. Conclusion 
Outstanding contributions from Nature have paved the way in drug discovery and allowed 
the establishment of conventional therapies for the treatment of the majority of human 
diseases, including cancer. Whereas plants have been the most common source of active 
molecules throughout the centuries, the now unraveling potential of marine and microbial 
sources is bound to provide highly active compounds with a myriad of biological activities 
which may improve the therapeutic options available for many human diseases in a nearby 
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future. Many compounds from plant, marine and microbial sources have been studied on 
PC targets. Therapies which target both androgen-dependent and –independent PC cells 
and can thus circumvent the mechanisms of PC recurrence have been exhaustively 
investigated. In this setting, molecules such as AT-101, EPI-001, trabectedin, temsirolimus 
and everolimus, ixabepilone A and sagupilone, docetaxel and cabazitaxel, irofulven, PG490-
88Na, as well as several pentacyclic triterpenoids, which have been discussed herein, are 
excellent examples of NPs with an impact on PC. 
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